Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Pearce

Showing results (111-120 of 151) with videos related to

Pageof 16
Sort By:
Trials|November 11, 2018
ALternatives To prophylactic Antibiotics for the treatment of Recurrent urinary tract infection in women (ALTAR): study protocol for a multicentre, pragmatic, patient-randomised, non-inferiority trialRebecca Forbes, Ased Ali, Alaa Abouhajar, et al.
Eye (London, England)|January 16, 2026
Aflibercept 8 mg treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: guidance from a UK expert panelRichard Gale, Mahmoud Husseiny Awad, Clare Bailey, et al.
Eye (London, England)|May 12, 2025
Visual outcome following initiation of first injection versus after three monthly doses of aflibercept 2 mg for treatment naïve age-related macular degeneration to inform clinical trial designs: PRECISE Report No. 6Swati Chandak, Sarega Gurudas, Raheeba Pakeer Muhammed, et al.
Eye (London, England)|May 6, 2024
Impact of treat and extend criteria on proportions that can be extended after loading phase of 2 mg aflibercept therapy for neovascular age related macular degeneration: PRECISE Report 5Sridevi Thottarath, Sarega Gurudas, Swati Chandak, et al.
Acta Ophthalmologica|April 27, 2018
A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS)Jana Stefanickova, Jose Cunha-Vaz, Michael Ulbig, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|February 2, 2021
Anti-VEGF intravitreal injections in the era of COVID-19: responding to different levels of epidemic pressureJean-François Korobelnik, Anat Loewenstein, Bora Eldem, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|April 25, 2020
Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemicJean-François Korobelnik, Anat Loewenstein, Bora Eldem, et al.
Eye (London, England)|December 15, 2023
Baseline characteristics of eyes with early residual fluid post loading phase of aflibercept therapy in neovascular AMD: PRECISE study report 3Shruti Chandra, Sarega Gurudas, Ian Pearce, et al.
Eye (London, England)|October 23, 2025
Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO studyTunde Peto, Ian Pearce, James Talks, et al.
BMJ (Clinical Research Ed.)|March 10, 2022
Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trialChris Harding, Helen Mossop, Tara Homer, et al.
Pageof 16

Showing results (111-120 of 151) with videos related to

Sort By:
Pageof 16
Trials|November 11, 2018
ALternatives To prophylactic Antibiotics for the treatment of Recurrent urinary tract infection in women (ALTAR): study protocol for a multicentre, pragmatic, patient-randomised, non-inferiority trialRebecca Forbes, Ased Ali, Alaa Abouhajar, et al.
Eye (London, England)|January 16, 2026
Aflibercept 8 mg treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: guidance from a UK expert panelRichard Gale, Mahmoud Husseiny Awad, Clare Bailey, et al.
Eye (London, England)|May 12, 2025
Visual outcome following initiation of first injection versus after three monthly doses of aflibercept 2 mg for treatment naïve age-related macular degeneration to inform clinical trial designs: PRECISE Report No. 6Swati Chandak, Sarega Gurudas, Raheeba Pakeer Muhammed, et al.
Eye (London, England)|May 6, 2024
Impact of treat and extend criteria on proportions that can be extended after loading phase of 2 mg aflibercept therapy for neovascular age related macular degeneration: PRECISE Report 5Sridevi Thottarath, Sarega Gurudas, Swati Chandak, et al.
Acta Ophthalmologica|April 27, 2018
A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS)Jana Stefanickova, Jose Cunha-Vaz, Michael Ulbig, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|February 2, 2021
Anti-VEGF intravitreal injections in the era of COVID-19: responding to different levels of epidemic pressureJean-François Korobelnik, Anat Loewenstein, Bora Eldem, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|April 25, 2020
Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemicJean-François Korobelnik, Anat Loewenstein, Bora Eldem, et al.
Eye (London, England)|December 15, 2023
Baseline characteristics of eyes with early residual fluid post loading phase of aflibercept therapy in neovascular AMD: PRECISE study report 3Shruti Chandra, Sarega Gurudas, Ian Pearce, et al.
Eye (London, England)|October 23, 2025
Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO studyTunde Peto, Ian Pearce, James Talks, et al.
BMJ (Clinical Research Ed.)|March 10, 2022
Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trialChris Harding, Helen Mossop, Tara Homer, et al.
Pageof 16